Exemestane 25 mg

• Exemestane 25 mg
• Brand: Magnus Pharmaceuticals
• Content: 30 tablets | 25 mg per tablet
• Manufactured in: Europe

Product Overview

Exemestane 25 mg is a third-generation, steroidal aromatase inhibitor (AI) that irreversibly binds the CYP19 enzyme, producing sustained suppression of systemic estrogen. Widely used in hormonal modulation and post-cycle therapy (PCT) research, it is particularly effective for testosterone-boosting protocols and estrogen-dependent tumor investigations.

A single 25 mg dose lowers estradiol by 60–80% within 12 hours and sustains suppression for up to 48 hours due to its ~24–27 hour half-life. Studies confirm its effectiveness in raising LH, FSH, and modestly increasing endogenous testosterone without altering adrenal androgens. This compound is listed on WADA’s S4 prohibited list for hormone modulators.

Key Research Highlights

• Irreversible aromatase blockade: Covalently deactivates CYP19, maintaining estrogen suppression post-clearance [ScienceDirect]
• 24-hour pharmacokinetics:Half-life of 24–27 hours ensures stable once-daily dosing in long-term hormonal protocols [PubMed]
• Testosterone-to-estradiol ratio:25 mg/day improved T:E ratios in male models without affecting DHEA/androstenedione [FDA data]
• Bone & lipid impact (chronic use): Long-term data show BMD and HDL / LDL — relevant for extended-duration studies [PubMed, PMC]
• Shelf-stable & lab-friendly: Film-coated tablets remain potent at 25 °C without refrigeration [ICH Stability, MSDS]

Suggested Laboratory Applications

Irreversible aromatase inhibition and estrogen-suppression modeling

Testosterone enhancement in male hypogonadism models

PCT studies for anabolic-recovery protocols

LH/FSH modulation research

Tamoxifen-resistant estrogen-tumor studies

Technical Specifications

Detection Window

Medium-long, varies with protocol

Documented Benefits

E2 by 60–80%, LH/FSH, T, stable estrogen suppression

Main Risks

BMD, lipid shifts, fatigue, joint pain, hot flashes

Total Active Compound

750 mg per carton (25 mg 30 tablets)

Shelf-life

36 months (manufacturer specification)

PubChem-Supported Research Insights

Irreversible suppression of estrogen via steroidal aromatase inhibition

Rapid E2 reduction within 12 hours of dosing

Increases T: E ratio in male subjects without disturbing adrenal steroids

Maintains hormonal control for up to 48 hours post-dose

Applied in resistant ER+ tumor model studies and androgen support trials

Documented Research Side Effects

Common: Hot-flushes, arthralgia, fatigue, insomnia

Long-term: Bone mineral density reduction, HDL/LDL

Other: Menopausal symptoms and mood variations

Listed under WADA S4 — prohibited in all competitive levels

Handling & Compliance

For Research Use Only — Not for human or veterinary useStore at 15–25°C, protect from light and moisturePurchase confirms qualified researcher statusListed on WADA Prohibited List S4 — any exposure may result in a positive test